leadf
logo-loader
viewAequus Pharmaceuticals Inc.

Full interview: Aequus Pharmaceuticals off to a great start in 2020 after record 4th quarter in 2019

Aequus Pharmaceuticals (CVE:AQS-OTCQB: AQSZF) Chairman and CEO Doug Janzen joined Steve Darling from Proactive Vancouver as the company released their 2019 financial numbers which saw Aequus set a revenue record in the 4th quarter.

Janzen also discussed 2020 and where he sees the best opportunities for growth including the lucrative dry eye market and their partnership with Medicom.

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.115 CAD

TSX-V:AQS
Market: TSX-V
Market Cap: $12.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

FYI Resources welcomes 'unprecedented response' to $6 million fundraise

FYI Resources Ltd's (ASX:FYI) Roland Hill caught up with Proactive's Andrew Scott after announcing they've received firm commitments to raise up to $6 million through a strongly supported placement to sophisticated and professional investors. It'll go towards advancing its strategy of producing...

2 hours, 2 minutes ago

2 min read